Institutional members access full text with Ovid®

Share this article on:

Cytomegalovirus Infection in Liver Transplant Recipients

Hamilton, Keith W. MD; Blumberg, Emily A. MD

Infectious Diseases in Clinical Practice: January 2012 - Volume 20 - Issue 1 - p 32–41
doi: 10.1097/IPC.0b013e31823c4817
Review Articles

Cytomegalovirus (CMV) is one of the most common opportunistic infections in liver transplant recipients and has significant impact on patient outcomes. A number of strategies to prevent and treat CMV disease in these patients have been developed, but despite these advances, CMV infection still poses a unique and significant risk to liver transplant recipients. Liver transplant patients provide distinctive challenges, and a significant amount of controversy exists in their management compared to other organ transplant recipients because many studies evaluating the management of CMV are not specific to this population. This article reviews the effect of CMV on liver transplant recipients and the ongoing challenges in treatment and prevention of these complications.

From the Division of Infectious Diseases, Hospital of the University of Pennsylvania, Philadelphia, PA.

Correspondence to: Keith W. Hamilton, MD, Hospital of the University of Pennsylvania, 3400 Spruce St, 3 Silverstein Bldg, Suite E, Philadelphia, PA 19104. E-mail

Dr Hamilton has no funding or conflicts of interest to disclose.

Dr Blumberg is currently a member of the Pfizer Data Safety Monitoring Board and was both an investigator and a consultant for Roche Pharmaceuticals in 2010.

© 2012 Lippincott Williams & Wilkins, Inc.